Tagrisso Tablets Clinical Experience Investigation (All Case Investigation)

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

All Patients Treated With the Product

Study type

Observational

Funder types

Industry

Identifiers

NCT02756039
D5160C00025

Details and patient eligibility

About

Clinical experience investigation (CEI) is to be conducted to confirm the following to characterise safety and efficacy of Tagrisso Tablets in actual clinical use. Incidence of adverse drug reactions (ADRs) in actual clinical use Factors which may affect safety and efficacy of the product (especially analysis of the incidence and risk factors of interstitial lung disease (ILD) events) Information of ADRs not expected from "Precautions for Use" of the package insert in Japan

Enrollment

3,494 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

patients treated with the product

Exclusion criteria

No Account (NA)

Trial contacts and locations

47

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems